Pediatric Gastrointestinal Outcomes During the Post-Acute Phase of COVID-19

Dazheng Zhang, MS[1,2,*], Ronen Stein, MD[3,4,*], Yiwen Lu, BS[1,5,*], Ting Zhou, MD, PhD[1,2,*], Yuqing Lei, MS[1,2], Lu Li, BS[1,5], Jiajie Chen, PhD[1,2], Jonathan Arnold, MD[6], Michael J. Becich, MD, PhD[7], Elizabeth A. Chrischilles, PhD[8], Cynthia H. Chuang, MD, MS[9], Dimitri A Christakis, MD, MPH[10], Daniel Fort, PhD, MPH[11], Carol R. Geary, PhD, MBA, RN[12], Mady Hornig, MA, MD[13], Rainu Kaushal, MD[14], David M. Liebovitz, MD[15], Abu Saleh Mohammad Mosa, PhD, MS, FAMIA[16], Hiroki Morizono, PhD[17], Parsa Mirhaji, MD, PhD[18], Jennifer L. Dotson, MD, MPH[19], Claudia Pulgarin, MA, MS[20], Marion R. Sills, MD, MPH[21,22], Srinivasan Suresh, MD, MBA[23,24], David A. Williams, PhD[25], Robert N. Baldassano, MD[3,4], Christopher B. Forrest, MD, PhD[26], Yong Chen, PhD[1,2,27,5,28,29] on behalf of the RECOVER Initiative

Affiliation:

[1]The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, United States,
[2]Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States,
[3]Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, United States,
[4]Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States,
[5]Applied Mathematics and Computational Science, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, United States,
[6]Division of General Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States,
[7]Department of Biomedical Informatics, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States,
[8]Department of Epidemiology, College of Public Health, The University of Iowa, Iowa City, IA, United States,
[9]Division of General Internal Medicine, Penn State College of Medicine, Hershey, PA, United States,
[10]Center for Child Health, Behavior, and Development, Seattle Children's Research Institute, Seattle, WA, United States,
[11]Ochsner Center for Outcomes Research, Ochsner Health, New Orleans, LA, United States,
[12]College of Medicine, University of Nebraska Medical Center, Omaha, NE, United States,
[13]Department of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, United States,
[14]Department of Population Health Sciences, Weill Cornell Medical College, New York, NY, United States,
[15]Division of General Internal Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States,
[16]Department of Biomedical Informatics, Biostatistics and Medical Epidemiology, University of Missouri School of Medicine, Columbia, MO, United States,

[17]Center for Genetic Medicine Research, Children's National Hospital, Washington, DC, United States,
[18]Institute for Clinical Translational Research, Albert Einstein College of Medicine, New York, NY, United States,
[19]Division of Gastroenterology, Hepatology and Nutrition, The Ohio State University College of Medicine, Columbus, OH, United States,
[20]Department of Population Health, New York University Grossman School of Medicine, New York, NY, United States,
[21]Department of Research, OCHIN, Inc., Portland, OR, United States,
[22]University of Colorado Anschutz Medical Campus, Aurora, CO, United States,
[23]Divisions of Health Informatics & Emergency Medicine, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States,
[24]UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, United States
[25]Department of Anesthesiology, University of Michigan, Ann Arbor, MI, United States,
[26]Applied Clinical Research Center, Children's Hospital of Philadelphia, Philadelphia, PA, United States,
[27]Penn Institute for Biomedical Informatics (IBI), Philadelphia, PA, United States,
[28]Leonard Davis Institute of Health Economics, Philadelphia, PA, United States,
[29]Penn Medicine Center for Evidence-based Practice (CEP), Philadelphia, PA, United States.
[*]Contributed equally

Correspondence to: Yong Chen, Ph.D.
University of Pennsylvania
Blockley Hall 602, 423 Guardian Drive
Philadelphia, PA 19104
Office: 215-746-8155
E-mail: ychen123@upenn.edu

Authorship Statement
Authorship has been determined according to ICMJE recommendations.

Summary

Background: The impact of COVID-19 on gastrointestinal (GI) outcomes in children during the post-acute and chronic phases of the disease is not well understood.

Methods: We conducted a retrospective cohort study across twenty-nine healthcare institutions from March 2020 to September 2023, including 413,455 pediatric patients with confirmed SARS-CoV-2 infection and 1,163,478 controls without infection. Infection was confirmed via polymerase chain reaction (PCR), serology, antigen tests, or clinical diagnosis of COVID-19 and related conditions. We examined the incidence of predefined GI symptoms and disorders during the post-acute (28 to 179 days post-infection) and chronic (180 to 729 days post-infection) phases. The adjusted risk ratios (aRRs) were calculated using stratified Poisson regression, with stratification based on propensity scores.

Results: Our cohort comprised 1,576,933 patients, with females representing 48.0% of the sample. The analysis revealed that children with SARS-CoV-2 infection had an increased risk of developing at least one GI symptom or disorder in both the post-acute (8.64% vs. 6.85%; aRR 1.25, 95% CI 1.24-1.27) and chronic phases (12.60% vs. 9.47%; aRR 1.28, 95% CI 1.26-1.30) compared to uninfected peers. Specifically, the risk of abdominal pain was higher in COVID-19 positive patients during the post-acute phase (2.54% vs. 2.06%; aRR 1.14, 95% CI 1.11-1.17) and chronic phase (4.57% vs. 3.40%; aRR 1.24, 95% CI 1.22-1.27).

Interpretation: Children with a history of SARS-CoV-2 infection are at an increased risk of GI symptoms and disorders during the post-acute and chronic phases of COVID-19. This highlights the need for ongoing monitoring and management of GI outcomes in this population.

Research in Context

Evidence before this study

We searched PubMed, Scopus, and Google Scholar databases up to September 2023 for studies assessing the incidence and risk of gastrointestinal (GI) symptoms and disorders in children following viral infections, including COVID-19. We included studies published in any language and involving various methodologies (observational studies, cohort studies, and clinical trials). Our search terms included "COVID-19," "SARS-CoV-2," "gastrointestinal symptoms," "children," "post-acute," and "chronic." The evidence prior to this study suggested an increased risk of GI disorders in adults after viral infections but was less definitive for the pediatric population.

Added value of this study

This study significantly extends the existing literature by specifically examining the risk of GI symptoms and disorders in the pediatric population during the post-acute and chronic phases of COVID-19. Using a large retrospective cohort design encompassing over 1.5 million children and adolescents from 29 healthcare institutions, our analysis provides robust evidence of increased GI symptoms like abdominal pain, diarrhea, and constipation among COVID-19 positive patients compared to non-infected peers. It is one of the largest studies of its kind and the first to provide such comprehensive data for the U.S. pediatric population, with follow-up extending up to two years post-infection.

Implications of all the available evidence

The findings underscore the importance of monitoring children and adolescents for persistent GI symptoms following COVID-19, suggesting that these symptoms may be more common and prolonged than previously recognized. These insights are crucial for pediatric healthcare providers and could influence guidelines for the follow-up care of children recovering from

COVID-19. The study also highlights the need for future research to explore the underlying mechanisms of post-acute and chronic GI symptoms in children to develop targeted interventions and improve long-term outcomes.

Keywords: Children; COVID-19; Gastrointestinal outcomes; Post-acute phase;

Introduction

Long COVID, also known as the Post-Acute Sequelae of SARS-CoV-2 (PASC), was initially identified primarily in adults, but its emergence has also raised concerns for the pediatric population. In the United States (US), depending on the definition used and the study population, PASC is reported to affect 1.3% of children, a rate lower than that reported in some studies for adults (6.7%)[1,2]. This may not be surprising as there are important differences in the presentation and outcomes of acute SARS-CoV-2 infection between children and adults. Children can have different symptoms compared to adults and tend to have a milder disease course, or even one that is asymptomatic, with a lower risk of hospitalization or death–particularly children without pre-existing conditions[3–5]. Given these differences in acute infection, as well as the differences in prevalence between children and adults, the characteristics of PASC require further study in children.

Multiple organ systems can be affected in PASC, including the gastrointestinal (GI) tract. The risk of GI symptoms and disorders, including abdominal pain, diarrhea, constipation, vomiting, bloating, irritable bowel syndrome (IBS), and gastroesophageal reflux disease (GERD) was increased in the one year after SARS-CoV-2 infection amongst adults.[6] This phenomenon of chronic GI symptoms potentially developing after infection was well-described in adults before the SARS-CoV-2 pandemic with post-infectious IBS associated with acute gastroenteritis[7,8] and post-viral gastroparesis seen in association with several respiratory and GI viruses[9]. Children are also at risk for developing an array of lingering GI symptoms after an acute infection but in contrast to adults, pediatric patients predominantly present with chronic abdominal pain and constipation[10]. As the data regarding the long-term effect of SARS-CoV-2 on the GI tract

amongst children is limited[11], it is unclear if children have the same risks of GI conditions during the post-acute phase of COVID-19 as has been seen with adults.

In this retrospective cohort study, we aimed to investigate the risk of GI symptoms and disorders during the post-acute and chronic phases of COVID-19 illness among children and adolescents. We used electronic health cohort (EHR) data sourced from twenty-nine children's hospitals and health institutions in the US. Specifically, we first estimated the incidence of any GI symptoms and disorders associated with SARS-CoV-2 infection. We further evaluated whether the SARS-CoV-2 infection increases the risk of GI symptoms and disorders. To the best of our knowledge, our investigation has the longest follow-up duration (two years) and is the largest study reported for children and adolescents that assesses the risks of COVID-19 infection for GI symptoms and diseases in the US.

Methods

Data Sources

This study is part of the NIH Researching COVID to Enhance Recovery (RECOVER) Initiative (https://recovercovid.org/), which aims to learn the long-term effects of COVID-19. Twenty-nine health institutions contributed to the data. Specifically, the health institutions are Children's Hospital of Philadelphia (CHOP), Cincinnati Children's Hospital Medical Center, Children's Hospital Colorado, Columbia University Irving Medical Center, Duke University, The Ohio State University, Ann & Robert H. Lurie Children's Hospital of Chicago, Medical College of Wisconsin, University of Michigan, University of Missouri, Montefiore, Medical University of

South Carolina, Children's National Medical Center, Nationwide Children's Hospital, Nicklaus Children's Hospital, the University of Nebraska Medical Center, The Nemours Foundation, Northwestern University, New York University School of Medicine, OCHIN, Inc., Ochsner Health System, University of Pittsburgh, Penn State University, Seattle Children's Hospital, Stanford University, University of California San Francisco, University of South Florida and Tampa, Vanderbilt University Medical Center, and Weill Cornell Medical College. The data are standardized according to the National Patient-centered Clinical Research Network[12] (PCORnet) Common Data Model. The criteria for selecting the patients are submitted to the CHOP Coordinating Center.

Cohort Construction

Our study period spanned from March 2020 to September 2023, with a cohort entry date cutoff of March 2023 (179 days before the end of the study period). Our study focused on individuals aged not above 18 who had at least one visit within 24 months to 7 days before the index date and subsequently had another encounter 28 days to 729 days after the index date. For the cohort defined as having a positive COVID-19 status, we included patients who had at least one documented SARS-CoV-2 infection, including positive polymerase chain reaction (PCR) tests, serology, antigen tests, diagnosed COVID-19, or PASC. We excluded the patients with the diagnosis of multisystem inflammatory syndrome in children (MIS-C) from the COVID-19 positive cohort. The cohort entry date was defined as the first index date of the documented SARS-CoV-2 infection. As for the COVID-19 negative cohort, we selected pediatric patients who did not have the documented SARS-CoV-2 infection or MIS-C diagnosis during the same

study period and who had at least one negative COVID-19 test result. The index date for the cohort with COVID-19 negative was determined by randomly choosing a negative test result. The selection for the COVID-19 positive and negative patients was included in **Figure 1**.

Defining GI Outcomes

We explored nine predefined GI symptoms and disorders within each follow-up period (28 days to 729 days after the cohort entry date). The GI signs or symptoms were abdominal pain, bloating, constipation, diarrhea, nausea, and vomiting. The GI disorders were functional dyspepsia, GERD, and IBS. The GI symptoms and disorders were systematically categorized using the ICD-10-CM codes. For reference, the ICD-10-CM codes utilized in our analysis have been provided in **Section S11** in the Supplement.

Patient Characteristics

We made an extensive array of patient characteristics and identified a set of confounders. These included factors such as age at cohort entry, sex (female, male), race and ethnicity (Non-Hispanic White (NHW), Non-Hispanic Black (NHB), Hispanic, Asian American/Pacific Islander (AAPI), Multiple, Other/Unknown), obesity status during the baseline period (from 24 months to 7 days before the cohort entry date). We also considered the month of cohort entry from March 2020 to March 2023, chronic condition status as defined by the Pediatric Medical Complexity Algorithm[13,14] (PMCA)—which categorizes conditions into no chronic condition, non-complex chronic condition, and complex chronic condition. Additionally, we included the site index for the cohort entry, and healthcare utilization indicated by the number of the inpatient, outpatient, and emergency department visits during the baseline period. Additionally, we analyzed the

number of unique medications or prescriptions (categorized as 0, 1, 2, >=3) and the count of negative tests conducted from 24 months to 7 days before the cohort entry date, also grouped as 0, 1, 2, >=3.

Statistical Methods

To illustrate the incidence of GI symptoms and disorders among COVID-19 positive patients in comparison to COVID-19 negative patients, we divided the number of patients having GI symptoms or disorders during the follow-up period but not at baseline by the total number of patients. We investigated the adjusted risk ratio (aRR) of the prespecified GI symptoms and disorders during the post-acute phase (spanning from 28 days to 179 days after the cohort entry date) and the chronic phase (ranging from 180 days to 729 days after the cohort entry date). To further enhance our analysis, we also investigated the risk of composites of any prespecified GI symptoms, GI disorders, and visits related to GI during the post-acute phase or chronic phase. Before fitting the model, we employed a cutoff incidence value of 0.1%[15] to prevent the implications of model overfitting for rare GI outcomes. Thus, we identified eight GI symptoms and disorders during the post-acute phase (spanning from 28 days to 179 days after the cohort entry date) and nine during the chronic phase (ranging from 180 days to 729 days after the cohort entry date). Specifically, in the post-acute phase, we assessed the risk of GI-related symptoms of abdominal pain, bloating, constipation, diarrhea, GERD, IBS, nausea, and vomiting. Likewise, during the chronic phase, we quantified the COVID-19-associated risk for all the GI symptoms and disorders listed in the Defining GI Outcomes subsection. To ensure the covariate balance between the COVID-19 positive and negative cohorts among the patient characteristics served as the confounders listed above, we used propensity-score-based stratification. The propensity score

model, derived from a logistic regression model with the outcome as the indicator of COVID-19 positivity, incorporated the patient characteristics as covariates. Confounder assessment utilized standardized mean differences (SMDs), with a cutoff value set at less than 0.1[16]. The aRR estimated risk quantification via a Poisson regression model stratified by the propensity score for the post-acute or chronic phases. Additionally, standard errors were reported based on sandwich estimators[17] to enhance result robustness.

Sensitivity Analysis

To ensure the robustness of our findings regarding GI symptoms and disorders, we systematically stratified the COVID-19 positive and negative cohorts into subgroups. Subsequent analyses were performed for each subgroup based on age (age<5, age from 5 to 11, age from 12 to 18), race/ethnicity (NHW, NHB, AAPI, and Hispanic), obesity status (obese/non-obese), sex (female/male), and medical history of diabetes (yes or no) or cardiovascular disorders (yes or no). The ICD-10-CM codes of diabetes and cardiovascular diseases were listed in **Section S13** in the Supplement. Detailed subgroup analyses were presented in **Sections S2-S7**. To further investigate the impact of hospitalization during the acute phase of COVID-19, we implemented our analysis method for the ICU admission, hospitalized, and non-hospitalized groups in **Section S8**. Additionally, we explored the influence of varying severity levels of the acute phase (0 to 28 days after the cohort entry date) of COVID-19[18] by presenting results for the asymptomatic, mild, moderate, and severe groups in **Section S9**.

Negative Control Outcomes

Although we have incorporated an extensive array of confounders, the regression model might still be susceptible to residual bias, including unmeasured confounder bias. To reduce such bias from the estimation of aRR, we employed a calibration approach[19,20] involving thirty-seven negative control outcomes. Details regarding the calibration method were elucidated in **Section S10** of the Supplement, and the full list of negative control outcomes was provided in **Section S11**.

Results

We presented the descriptive analysis of both the COVID-19 positive and negative cohorts in **Table 1**. Our analysis included 1,576,933 patients. Among them, 756,618 (48.0%) were female. 74,369 (4.7%) were AAPI, 376, 728 (23.9%) were Hispanic, 267,056 (16.9%) were NHB, 671,358 (42.6%) were NHW, and 147,627 (9.4%) were other/unknowns, and 39,795 (2.5%) were multiple races. During the post-acute phase or the chronic phase, the incidence of individual and composite GI conditions was higher among COVID-19 positive patients than among COVID-19 negative patients. These incidences of GI symptoms and disorders were summarized in **Table 2**.

After fitting the propensity score model, the SMDs of all confounders for the COVID-19 positive and COVID-19 negative during the post-acute and chronic phase were balanced (less than 0.1). The plot for the SMDs and the equipoise plot are shown in **Section S1** of the Supplement. We showed the aRR for each GI symptom and disorder and composite outcomes during the post-acute phase or the chronic phase in **Figure 2**. We observed significantly elevated risks across

various GI outcomes when comparing COVID-19 positive patients to their COVID-19 negative counterparts. Specifically, the risk of experiencing abdominal pain was higher in the COVID-19 positive group (2.54%) compared to the COVID-19 negative group (2.06%), with an aRR of 1.14 (95% CI, 1.11-1.17). Bloating was more prevalent in the COVID-19 group (0.28% vs. 0.23%), with an aRR of 1.27 (95% CI, 1.18-1.37). Constipation also showed an increased incidence (2.94% vs. 2.42%), with an aRR of 1.20 (95% CI, 1.17-1.23). Diarrhea was reported more frequently (2.30% vs. 1.57%), with an aRR of 1.40 (95% CI, 1.36-1.43). Nausea and vomiting were similarly elevated, with nausea at 0.81% versus 0.56% (aRR, 1.27; 95% CI, 1.21-1.33) and vomiting at 2.98% versus 2.29% (aRR, 1.33; 95% CI, 1.30-1.36). GERD also exhibited a higher prevalence, 1.15% versus 1.00%, with an aRR of 1.19 (95% CI, 1.15-1.24). However, the risk of IBS did not have statistical significance after adjusting for confounding variables (0.10% vs. 0.11%; aRR, 0.91; 95% CI, 0.81-1.02). Additionally, the COVID-19 positive cohort exhibited increased risks for a composite of any of these GI signs or symptoms (8.24% vs. 6.45%; aRR, 1.26; 95% CI: 1.24-1.28), any of these GI disorders (1.27% vs. 1.12%; aRR, 1.19; 95% CI, 1.15-1.24), and any visits related to GI (8.64% vs. 6.85%; aRR, 1.19; 95% CI, 1.15-1.24).

In the chronic phase, COVID-19 positive patients exhibited elevated risks of various GI symptoms and symptoms and disorders compared to the COVID-19 negative cohort. The analysis revealed persistent higher risks for abdominal pain (4.57% vs. 3.40%; aRR, 1.24; 95% CI, 1.22-1.27), bloating (0.44% vs. 0.34%; aRR, 1.30; 95% CI, 1.22-1.38), constipation (4.76% vs. 3.80%; aRR, 1.23; 95% CI, 1.21-1.25), diarrhea (3.34% vs. 2.14%; aRR, 1.48; 95% CI, 1.45-1.51), functional dyspepsia (0.13% vs. 0.11%; aRR, 1.14; 95% CI, 1.02-1.26), GERD (1.59% vs. 1.21%; aRR, 1.28; 95% CI, 1.24-1.33), IBS (0.22% vs 0.19%; aRR, 1.09; 95% CI, 1.00-1.18),

nausea (1.34% vs. 0.86%; aRR, 1.38; 95% CI, 1.33-1.43), and vomiting (4.25% vs. 3.05%; aRR, 1.40; 95% CI, 1.37-1.42). The heightened risk persisted for a composite of any of these GI signs or symptoms (12.19% vs. 9.13%; aRR, 1.26; 95% CI: 1.22-1.30), any of these GI disorders (1.82% vs. 1.40%; aRR, 1.28; 95% CI, 1.26-1.30), and any visits related to the GI (12.60% vs. 9.47%; aRR, 1.28; 95% CI, 1.26-1.30). These findings highlighted the persistent higher health risks among individuals with COVID-19 across a range of GI outcomes for the chronic phase. Moreover, when compared to the post-acute phase, the aRR for each GI outcome was higher in the chronic phase, indicating a prolonged impact of the infection on GI health.

We presented the results of the subgroup analysis for any visits related to GI in **Figure 3** by age, race/ethnicity, sex, cohort entry period, medical history of cardiovascular, diabetes, obesity status, the severity of the acute phase of COVID-19, and hospitalization status during the acute phase of COVID-19. We discovered that children under the age of five were at the highest risk for GI disorders or symptoms compared to the other two age groups. The aRR of GI-related visits increased with the severity of the acute phase of COVID-19, escalating from the mild group to the moderate group to the severity group. Additionally, the aRR of GI-related visits rose progressively from the non-hospitalized group to the hospitalization group, and finally to the ICU admission group.

Discussion

Principal Findings

In this population-based study, using a cohort of 1,576,933 patients not above the age of eighteen in the US, our results showed a significant increase in the risk of various GI outcomes associated with COVID-19. This heightened risk included abdominal pain, bloating, constipation, diarrhea, nausea, vomiting, and GERD during the post-acute or chronic phases of the illness. Notably, our findings indicated no statistically significant association between COVID-19 and IBS in the post-acute phase. Also, the aRR for functional dyspepsia in post-acute phase analysis was excluded due to its low level of occurrence (<0.1%)[15]. However, patients did exhibit an increased risk of experiencing IBS or functional dyspepsia during the chronic phase. Furthermore, our study underscored that COVID-19 was linked to an increased risk of presenting at least one GI sign or symptom, at least one GI disorder, and at least one GI-related visit during the post-acute phase or the chronic phase.

Comparison with Other Studies

Our findings align with prior research indicating that COVID-19 elevates the risk of GI symptoms such as nausea, diarrhea, and disorders like functional dyspepsia[21–26]. Many of these earlier studies were limited by insufficient sample sizes for precise estimations and restricted their risk assessments to specific geographic regions and time frames[21–24]. Our study is the largest study reported for children and adolescents that assesses the risks of COVID-19 infection for GI symptoms and diseases in the US. Our results are also consistent with a study that utilized the US Department of Veterans Affairs national health care databases to examine increased gastrointestinal symptom or disorder risks in the post-acute phase following infection[21]. Similar to our findings, this study observed a significantly higher risk of GI symptoms and disorders among SARS-CoV-2-infected individuals, including abdominal pain, bloating, constipation,

diarrhea, GERD, and vomiting. Our study uniquely focuses on children and adolescents, extending the evaluation of risk into the chronic phase (two years) beyond the post-acute period.

Interpretation

One potential biological mechanism underlying this association is the high expression of angiotensin-converting enzyme 2 on the brush border of the small intestinal mucosa.[27] Furthermore, SARS-CoV-2 infection has been shown to influence the gut microbiome[28], and this impact potentially persists beyond the post-acute phase[29]. Additionally, evidence from studies on prolonged viral fecal shedding[30] and the persistence of the virus in the GI tract[31] lends further support to the connection we have observed. A more profound understanding of the biological mechanisms will contribute to the development of targeted and effective interventions, ultimately improving outcomes for those affected by long-term GI disorders.

Strengths and Limitations

An outstanding feature of this study is its utilization of population-based databases within RECOVER. This large program facilitated the precise identification of comprehensive COVID-19 infection records and visits associated with GI symptoms and disorders throughout the entire study period in the US, thereby mitigating the potential for selection bias. Furthermore, it provided detailed and accurate information on infection status, reducing the likelihood of exposure misclassification bias. Notably, our investigation extended into the chronic phase, with a follow-up period of up to two years, representing one of the longest follow-up durations reported for children and adolescents exposed to COVID-19 infection in the US.

Our study has some limitations. Firstly, while we successfully achieved a balanced distribution of baseline covariates through matching, the propensity scores were constructed using only the variables accessible within our study databases. Nevertheless, the confounder list lays a solid foundation for our propensity score model, enhancing the reliability and validity of our analyses. Besides, it is important to highlight that our findings remained consistent and robust through sensitivity analyses aimed at addressing residue confounding by negative control outcomes. Moreover, despite the large sample size, our study might have ruled out small associations for rare events, such as functional dyspepsia in the post-acute phase. We ruled out functional dyspepsia in post-acute phase analysis due to its rare occurrence (<0.1%), but we observed an increased aRR in functional dyspepsia during the chronic phase. Furthermore, while our findings indicate a moderate reduction in the aRR for IBS during the post-acute phase, it is important to note that despite abdominal pain being a primary symptom of pediatric IBS, the Rome IV criteria[32] require a minimum of six months from symptom onset for a diagnosis of IBS. This timeframe typically extends beyond the post-acute period, complicating the diagnosis within that phase. Additionally, the misclassification of documented SARS-CoV-2 infection can be a problem within EHR. However, recent studies[33] provided a novel statistical method to account for the misclassified documented infection with prior knowledge about the prespecified range of misclassification rates given the patients get infected with SARS-CoV-2 infection or diagnosed with COVID-19. Implementing this statistical approach helps to mitigate some of the biases introduced by EHR misclassifications and strengthens the reliability of our findings. However, future studies will need to continue refining these techniques and exploring additional methods to further reduce the impact of misclassification on GI outcomes.

In addition, even with the chronic period post-infection, the 6-month requirement and difficulties getting GI specialist appointments amidst ongoing healthcare strain and other pandemic-related impediments imply that there may have been under-ascertainment of pediatric IBS in this large, EHR-based study. This is underscored by our finding of an elevated frequency of abdominal pain, the core symptom of IBS, in both post-infection periods, and suggests that even longer post-infection surveillance periods may be warranted. This ongoing research is pivotal not only for improving the clinical management of children with persistent GI symptoms and disorders, but also for informing public health strategies aimed at preventing long-term consequences of SARS-CoV-2 infection.

Disclaimer

This content is solely the responsibility of the authors and does not necessarily represent the official views of the RECOVER Initiative, the NIH, or other funders.

Author Contributions

Authorship was determined using *ICMJE* recommendations. DZ, RS, TZ, and YL designed methods and experiments; CF provided the datasets for data analysis; DZ and YL conducted data analysis; all coauthors interpreted the results and provided instructive comments; DZ, RS, TZ, and YL drafted the main manuscript. All coauthors provided critical edits to the early draft and approved the final version of the manuscript. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Funding

This research was funded in part by the National Institutes of Health (NIH) Agreement OTA OT2HL161847-01 as part of the Researching COVID to Enhance Recovery (RECOVER) Research Initiative.

Potential Conflicts of Interest

Dr. Becich reports PCORnet funding as MPI for the PaTH Clinical Research Network. All other authors have no conflicts of interest to report.

Ethical Approval

This study was approved by the University of Pennsylvania's institutional review board (No. 851604), with a waiver of informed consent.

Data Availability

The data can be shared with the request to the RECOVER initiative.

Acknowledgments

This study is part of the NIH Researching COVID to Enhance Recovery (RECOVER) Initiative, which seeks to understand, treat, and prevent the post-acute sequelae of SARS-CoV-2 infection (PASC). For more information on RECOVER, visit https://recovercovid.org/.

We would like to thank the National Community Engagement Group (NCEG), all patients, caregivers, and community Representatives, and all the participants enrolled in the RECOVER

Initiative. A special thanks to patient representatives Megan Carmilani and Etienne Carignan for their helpful comments and suggestions.

Key Figures and Tables

Figure 1. Attrition table for COVID-19 positive cohort and COVID-19 negative cohort.



Table 1. Patient characteristics of COVID-19 negative cohort, COVID-19 positive cohort, and the overall cohort.

	Negative (N=1,163,478)	**Positive** (N=413,455)	**Overall** (N=1,576,933)
Age at Cohort Entry			
<1	132283 (11.4%)	57135 (13.8%)	189418 (12.0%)
1-4	349078 (30.0%)	105599 (25.5%)	454677 (28.8%)
5-11	366863 (31.5%)	121287 (29.3%)	488150 (30.0%)
12-18	315254 (27.1%)	129434 (31.3%)	444688 (28.2%)
Sex			
Female	554659 (47.7%)	201959 (48.8%)	756618 (48.0%)
Male	608819 (52.3%)	211496 (51.2%)	820315 (52.0%)

Race/ Ethnicity			
Asian Americans and Pacific Islanders	54636 (4.7%)	19733 (4.8%)	74369 (4.7%)
Hispanic	274391 (23.6%)	102337 (24.8%)	376728 (23.9%)
Multiple	30931 (2.7%)	8864 (2.1%)	39795 (2.5%)
Non-Hispanic Black	195492 (16.8%)	71564 (17.3%)	267056 (16.9%)
Non-Hispanic White	499954 (43.0%)	171404 (41.5%)	671358 (42.6%)
Other/Unknown	108074 (9.3%)	39553 (9.6%)	147627 (9.4%)
Site Index			
A	89810 (7.7%)	27544 (6.7%)	117354 (7.4%)
B	139352 (12.0%)	53775 (13.0%)	193127 (12.2%)
C	65449 (5.6%)	15031 (3.6%)	80480 (5.1%)
D	14396 (1.2%)	5102 (1.2%)	19498 (1.2%)
E	39273 (3.4%)	8230 (2.0%)	47503 (3.0%)
F	9426 (0.8%)	4257 (1.0%)	13683 (0.9%)
G	42978 (3.7%)	10539 (2.5%)	53517 (3.4%)
H	14386 (1.2%)	5743 (1.4%)	20129 (1.3%)
I	28785 (2.5%)	9193 (2.2%)	37978 (2.4%)
J	13709 (1.2%)	5054 (1.2%)	18763 (1.2%)
K	80676 (6.9%)	36989 (8.9%)	117665 (7.5%)
L	105681 (9.1%)	22904 (5.5%)	128585 (8.2%)
M	43508 (3.7%)	13741 (3.3%)	57249 (3.6%)
N	3950 (0.3%)	1553 (0.4%)	5503 (0.3%)
O	89364 (7.7%)	24724 (6.0%)	114088 (7.2%)
P	38952 (3.3%)	16529 (4.0%)	55481 (3.5%)
Q	30009 (2.6%)	8961 (2.2%)	38970 (2.5%)
R	110479 (9.5%)	50943 (12.3%)	161422 (10.2%)
S	23140 (2.0%)	14527 (3.5%)	37667 (2.4%)
T	3339 (0.3%)	1383 (0.3%)	4722 (0.3%)
U	12724 (1.1%)	23894 (5.8%)	36618 (2.3%)
V	15556 (1.3%)	4836 (1.2%)	20392 (1.3%)
W	26780 (2.3%)	4831 (1.2%)	31611 (2.0%)
X	38333 (3.3%)	12499 (3.0%)	50832 (3.2%)
Y	1039 (0.1%)	772 (0.2%)	1811 (0.1%)
Z	35262 (3.0%)	11130 (2.7%)	46392 (2.9%)
AA	4719 (0.4%)	2219 (0.5%)	6938 (0.4%)
AB	30205 (2.6%)	11412 (2.8%)	41617 (2.6%)
AC	12198 (1.0%)	5140 (1.2%)	17338 (1.1%)
Cohort Entry Period			
03/2020 - 05/2020	19779 (1.7%)	3793 (0.9%)	23572 (1.5%)

06/2020 - 08/2020	69928 (6.0%)	12219 (3.0%)	82147 (5.2%)
09/2020 - 11/2020	98028 (8.4%)	20709 (5.0%)	118737 (7.5%)
12/2020 - 02/2021	98016 (8.4%)	37326 (9.0%)	135342 (8.6%)
03/2021 - 05/2021	107170 (9.2%)	22859 (5.5%)	130029 (8.2%)
06/2021 - 08/2021	107358 (9.2%)	23796 (5.8%)	131154 (8.3%)
09/2021 - 11/2021	162532 (14.0%)	38181 (9.2%)	200713 (12.7%)
12/2021 - 02/2022	124071 (10.7%)	123976 (30.0%)	248047 (15.7%)
03/2022 - 05/2022	93889 (8.1%)	31854 (7.7%)	125743 (8.0%)
06/2022 - 08/2022	73250 (6.3%)	48037 (11.6%)	121287 (7.7%)
09/2022 - 11/2022	113927 (9.8%)	24082 (5.8%)	138009 (8.8%)
12/2022 - 03/2023	95530 (8.2%)	26623 (6.4%)	122153 (7.7%)
Obesity			
Non-Obese	660682 (56.8%)	208580 (50.4%)	869262 (55.1%)
Obese	378266 (32.5%)	163729 (39.6%)	541995 (34.4%)
Unknown	124530 (10.7%)	41146 (10.0%)	165676 (10.5%)
PMCA Index			
0	811758 (69.8%)	289146 (69.9%)	1100904 (69.8%)
1	193920 (16.7%)	69616 (16.8%)	263536 (16.7%)
2	157800 (13.6%)	54693 (13.2%)	212493 (13.5%)
Number of Tests			
0	856237 (73.6%)	245524 (59.4%)	1101761 (69.9%)
1	193189 (16.6%)	87927 (21.3%)	281116 (17.8%)
2	62803 (5.4%)	37458 (9.1%)	100261 (6.4%)
2+	51249 (4.4%)	42546 (10.3%)	93795 (5.9%)
Number of Drugs			
0	278662 (24.0%)	80867 (19.6%)	359529 (22.8%)
1	137488 (11.8%)	45771 (11.1%)	183259 (11.6%)
2	111410 (9.6%)	40194 (9.7%)	151604 (9.6%)
2+	635918 (54.7%)	246623 (59.6%)	882541 (56.0%)

Table 2. Incidence table in % for post-acute phase or chronic phase of COVID-19 infection.

Category	Outcome	Entire follow-up (%)		Post-acute phase (%)		Chronic phase (%)	
		COVID-19	Control	COVID-19	Control	COVID-19	Control
Signs and symptoms	Abdominal Pain	6.59	5.09	2.54	2.06	4.57	3.40
	Bloating	0.68	0.53	0.28	0.23	0.44	0.34
	Constipation	6.88	5.58	2.94	2.42	4.76	3.80
	Diarrhea	5.32	3.54	2.30	1.57	3.34	2.14
	Nausea	2.00	1.33	0.81	0.56	1.34	0.86
	Vomiting	6.73	5.02	2.98	2.29	4.25	3.05
Disorders	GERD	2.41	1.92	1.15	1.00	1.59	1.21
	IBS	0.29	0.26	0.10	0.11	0.22	0.19
	Functional dyspepsia*	0.20	0.16	0.08	0.07	0.13	0.11
Composite	Any signs or symptoms	18.06	13.95	8.24	6.45	12.19	9.13
	Any disorders	2.71	2.19	1.27	1.12	1.82	1.40
	Any visits related to GI	18.67	14.52	8.64	6.85	12.60	9.47

***:** the incidence of the disorders and conditions lower than 0.1% during the post-acute phase after the SARS-CoV-2 infection

Figure 2. Adjusted risk ratio for the post-acute phase (28 days to 179 days after SARS-CoV-2 infection) and the chronic phase (180 days to 729 days after SARS-CoV-2 infection) comparing COVID-19 positive patients to COVID-19 negative patients.



Figure 3. A subgroup analysis for the adjusted risk ratios of GI visits between COVID-19 positive patients and COVID-19 negative patients. It details the adjusted risk ratios for two distinct phases: the post-acute phase, spanning from 28 to 179 days after SARS-CoV-2 infection, and the chronic phase, ranging from 180 to 729 days post-infection.



References

1 Vahratian A, Adjaye-Gbewonyo D, Lin J-MS, Saydah S. Long COVID in Children: United States, 2022. *NCHS Data Brief* 2023; : 1–6.

2 Vahratian A, Adjaye-Gbewonyo D, Lin J-MS, Saydah S. Long COVID in Children: United States, 2022. *NCHS Data Brief* 2023; : 1–6.

3 Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. *Acta Paediatr* 2020; **109**: 1088–95.

4 Pezzullo AM, Axfors C, Contopoulos-Ioannidis DG, Apostolatos A, Ioannidis JPA. Age-stratified infection fatality rate of COVID-19 in the non-elderly population. *Environ Res* 2023; **216**: 114655.

5 Hasnat F, Noman F, Moben AL, Sarker AS, Morshed J, Mutanabbi M. Difference in Clinical Patterns between COVID-19 Affected Children and Adults. *Mymensingh Med J* 2021; **30**: 1093–9.

6 Xu E, Xie Y, Al-Aly Z. Long-term gastrointestinal outcomes of COVID-19. *Nat Commun* 2023; **14**: 983.

7 Berumen A, Edwinson AL, Grover M. Post-infection Irritable Bowel Syndrome. *Gastroenterol Clin North Am* 2021; **50**: 445–61.

8 Thabane M, Marshall JK. Post-infectious irritable bowel syndrome. *World J Gastroenterol* 2009; **15**: 3591–6.

9 Bityutskiy LP, Soykan I, McCallum RW. Viral gastroparesis: a subgroup of idiopathic gastroparesis--clinical characteristics and long-term outcomes. *Am J Gastroenterol* 1997; **92**: 1501–4.

10 Pensabene L, Talarico V, Concolino D, *et al.* Postinfectious functional gastrointestinal disorders in children: a multicenter prospective study. *J Pediatr* 2015; **166**: 903-7.e1.

11 Thallapureddy K, Thallapureddy K, Zerda E, *et al.* Long-Term Complications of COVID-19 Infection in Adolescents and Children. *Curr Pediatr Rep* 2022; **10**: 11–7.

12 Fleurence RL, Curtis LH, Califf RM, Platt R, Selby J V, Brown JS. Launching PCORnet, a national patient-centered clinical research network. *Journal of the American Medical Informatics Association* 2014; **21**: 578–82.

13 Simon TD, Cawthon ML, Stanford S, *et al.* Pediatric medical complexity algorithm: a new method to stratify children by medical complexity. *Pediatrics* 2014; **133**: e1647–54.

14 Simon TD, Cawthon ML, Popalisky J, Mangione-Smith R. Development and validation of the pediatric medical complexity algorithm (PMCA) version 2.0. *Hosp Pediatr* 2017; **7**: 373–7.

15 Schuemie MJ, Ryan PB, Pratt N, *et al.* Large-scale evidence generation and evaluation across a network of databases (LEGEND): assessing validity using hypertension as a case study. *Journal of the American Medical Informatics Association* 2020; **27**: 1268–77.

16 Rubin DB. Using propensity scores to help design observational studies: application to the tobacco litigation. *Health Serv Outcomes Res Methodol* 2001; **2**: 169–88.

17 Zou G. A modified poisson regression approach to prospective studies with binary data. *Am J Epidemiol* 2004; **159**: 702–6.

18 Forrest CB, Burrows EK, Mejias A, *et al.* Severity of acute COVID-19 in children< 18 years old March 2020 to December 2021. *Pediatrics* 2022; **149**: e2021055765.

19 Schuemie MJ, Ryan PB, DuMouchel W, Suchard MA, Madigan D. Interpreting observational studies: why empirical calibration is needed to correct p-values. *Stat Med* 2014; **33**: 209–18.
20 Schuemie MJ, Hripcsak G, Ryan PB, Madigan D, Suchard MA. Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data. *Proceedings of the National Academy of Sciences* 2018; **115**: 2571–7.
21 Ghoshal UC, Ghoshal U, Rahman MM, *et al.* Post-infection functional gastrointestinal disorders following coronavirus disease-19: A case–control study. *J Gastroenterol Hepatol* 2022; **37**: 489–98.
22 Weng J, Li Y, Li J, *et al.* Gastrointestinal sequelae 90 days after discharge for COVID-19. *Lancet Gastroenterol Hepatol* 2021; **6**: 344–6.
23 Meringer H, Mehandru S. Gastrointestinal post-acute COVID-19 syndrome. *Nat Rev Gastroenterol Hepatol* 2022; **19**: 345–6.
24 Rizvi A, Patel Z, Liu Y, Satapathy SK, Sultan K, Trindade AJ. Gastrointestinal Sequelae 3 and 6 Months After Hospitalization for Coronavirus Disease 2019. *Clinical Gastroenterology and Hepatology* 2021; **19**: 2438-2440.e1.
25 Blackett JW, Wainberg M, Elkind MSV, Freedberg DE. Potential Long Coronavirus Disease 2019 Gastrointestinal Symptoms 6 Months After Coronavirus Infection Are Associated With Mental Health Symptoms. *Gastroenterology* 2022; **162**: 648-650.e2.
26 Xu E, Xie Y, Al-Aly Z. Long-term gastrointestinal outcomes of COVID-19. *Nat Commun* 2023; **14**: 983.
27 Mehandru S, Merad M. Pathological sequelae of long-haul COVID. *Nat Immunol* 2022; **23**: 194–202.
28 Donati Zeppa S, Agostini D, Piccoli G, Stocchi V, Sestili P. Gut Microbiota Status in COVID-19: An Unrecognized Player? *Front Cell Infect Microbiol* 2020; **10**. DOI:10.3389/fcimb.2020.576551.
29 Liu Q, Mak JWY, Su Q, *et al.* Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. *Gut* 2022; **71**: 544–52.
30 Wu Y, Guo C, Tang L, *et al.* Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. *Lancet Gastroenterol Hepatol* 2020; **5**: 434–5.
31 Gaebler C, Wang Z, Lorenzi JCC, *et al.* Evolution of antibody immunity to SARS-CoV-2. *Nature* 2021; **591**: 639–44.
32 Rome IV Criteria - Rome Foundation. https://theromefoundation.org/rome-iv/rome-iv-criteria/ (accessed Jan 22, 2024).
33 Wu Q, Tong J, Zhang B, *et al.* Real-world Effectiveness of BNT162b2 in Children and Adolescents. *medRxiv* 2023; : 2023.06.16.23291515.